-
公开(公告)号：US20120122782A1
公开(公告)日：2012-05-17
申请号：US13301739
申请日：2011-11-21
申请人： Catherine M. Rohloff , Guohua Chen , Zhongli Ding , Stephen Andrew Berry , Latha Pisharody Narayanan , Michael Desjardin
发明人： Catherine M. Rohloff , Guohua Chen , Zhongli Ding , Stephen Andrew Berry , Latha Pisharody Narayanan , Michael Desjardin
CPC分类号： A61K47/32 , A61K9/0019 , A61K9/1617 , A61K9/1623 , A61K9/1688 , A61K38/27 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/22 , A61K47/26 , A61K47/34 , A61K47/44
摘要： Formulations and methods are provided for improving the stability upon exposure to aqueous media of polypeptides present in non-aqueous suspension vehicles. In particular aspects of the invention, formulations are provided that comprise a complex of a metal ion and a polypeptide suspended in a non-aqueous, biocompatible suspension vehicle. Aggregation of individual polypeptide molecules is reduced when aqueous media is introduced to such formulations, serving to stabilize the polypeptide.
摘要翻译： 提供了制备和方法，用于提高暴露于存在于非水悬浮载体中的多肽的水性介质时的稳定性。 在本发明的特定方面，提供了包含悬浮在非水生物相容性悬浮载体中的金属离子和多肽的复合物的制剂。 当将水性介质引入这种制剂用于稳定多肽时，单个多肽分子的聚集被降低。
-
公开(公告)号：US20070015689A1
公开(公告)日：2007-01-18
申请号：US11471984
申请日：2006-06-21
申请人： Catherine Rohloff , Guohua Chen , Zhongli Ding , Stephen Berry , Latha Narayanan , Michael Desjardin
发明人： Catherine Rohloff , Guohua Chen , Zhongli Ding , Stephen Berry , Latha Narayanan , Michael Desjardin
IPC分类号： A61K38/27
CPC分类号： A61K47/32 , A61K9/0019 , A61K9/1617 , A61K9/1623 , A61K9/1688 , A61K38/27 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/22 , A61K47/26 , A61K47/34 , A61K47/44
摘要： Formulations and methods are provided for improving the stability upon exposure to aqueous media of polypeptides present in non-aqueous suspension vehicles. In particular aspects of the invention, formulations are provided that comprise a complex of a metal ion and a polypeptide suspended in a non-aqueous, biocompatible suspension vehicle. Aggregation of individual polypeptide molecules is reduced when aqueous media is introduced to such formulations, serving to stabilize the polypeptide.
摘要翻译： 提供了制备和方法，用于提高暴露于存在于非水悬浮载体中的多肽的水性介质时的稳定性。 在本发明的特定方面，提供了包含悬浮在非水生物相容性悬浮载体中的金属离子和多肽的复合物的制剂。 当将水性介质引入这种制剂用于稳定多肽时，单个多肽分子的聚集被降低。
-
公开(公告)号：US20060193918A1
公开(公告)日：2006-08-31
申请号：US11347562
申请日：2006-02-03
申请人： Catherine Rohloff , Guohua Chen , Andrew Luk , Rupal Ayer , Paul Houston , Michael Desjardin , Pauline Zamora , Stan Lam
发明人： Catherine Rohloff , Guohua Chen , Andrew Luk , Rupal Ayer , Paul Houston , Michael Desjardin , Pauline Zamora , Stan Lam
CPC分类号： A61K38/21 , A61K9/0004 , A61K9/0024 , A61K9/10 , A61K38/043 , A61K38/085 , A61K38/09 , A61K38/105 , A61K38/11 , A61K38/1808 , A61K38/185 , A61K38/191 , A61K38/2242 , A61K38/225 , A61K38/24 , A61K38/26 , A61K38/27 , A61K38/28 , A61K38/31 , A61K38/35 , A61K38/36 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/20 , A61K47/26 , A61K47/32 , Y10T29/494 , Y10T29/49826
摘要： A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be selected from the group consisting of benzyl benzoate, decanol, ethyl hexyl lactate, and mixtures thereof and the at least one polymer may be selected from the group consisting of a polyester, pyrrolidone, ester of an unsaturated alcohol, ether of an unsaturated alcohol, polyoxyethylenepolyoxypropylene block copolymer, and mixtures thereof. In one embodiment, the at least one solvent is benzyl benzoate and the at least one polymer is polyvinylpyrrolidone. A stable, nonaqueous suspension formulation that includes the nonaqueous, single-phase vehicle and an active agent, and a method of forming the same, are also disclosed.
-
公开(公告)号：US20060251618A1
公开(公告)日：2006-11-09
申请号：US11347601
申请日：2006-02-03
申请人： Paula Dennis , Michael Desjardin , Stan Lam , Kui Liu , James Matsuura , Latha Narayanan , Catherine Rohloff , Pauline Zamora
发明人： Paula Dennis , Michael Desjardin , Stan Lam , Kui Liu , James Matsuura , Latha Narayanan , Catherine Rohloff , Pauline Zamora
CPC分类号： A61K38/21 , A61F2250/0068 , A61K9/0004 , A61K9/0019 , A61K9/0024 , A61K9/10 , A61K9/1617 , A61K9/1623 , A61K9/1694 , A61K9/19
摘要： An implantable device includes a reservoir containing a suspension of an interferon in an amount sufficient to provide continuous delivery of the interferon at a therapeutically effective rate of 1 ng/day to 600 μg/day to maintain and achieve therapeutic blood or plasma levels of the interferon throughout a substantial period of the administration period.
摘要翻译： 可植入装置包括含有干扰素悬浮液的储存器，其量足以提供以1ng /天至600ug /天的治疗有效速率连续递送干扰素，以维持和实现干扰素的治疗血浆或血浆水平 在行政期间的相当长的一段时期。
-
公开(公告)号：US20060029551A1
公开(公告)日：2006-02-09
申请号：US11194889
申请日：2005-08-01
申请人： Kui Liu , Michael Desjardin
发明人： Kui Liu , Michael Desjardin
IPC分类号： A61K38/18 , A61K31/7012 , A61K9/14 , A61L9/04
CPC分类号： A61K9/1617 , A61K9/1623 , A61K9/19 , A61K31/7012 , A61K38/1816 , A61K47/12 , A61K47/183 , A61K47/26
摘要： A particle formulation includes an erythropoietin receptor agonist, a buffer, and a sugar, wherein the buffer and sugar stabilize the erythropoietin receptor agonist against aggregation.
摘要翻译： 颗粒制剂包括促红细胞生成素受体激动剂，缓冲剂和糖，其中缓冲液和糖使促红细胞生成素受体激动剂稳定聚集。
-
6.发明申请公开(公告)号：US20050276856A1
公开(公告)日：2005-12-15
申请号：US11183477
申请日：2005-07-18
申请人： Pamela Fereira , Michael Desjardin , Catherine Rohloff , Stephen Berry , Ekaterina Zlatkova-Karaslavova
发明人： Pamela Fereira , Michael Desjardin , Catherine Rohloff , Stephen Berry , Ekaterina Zlatkova-Karaslavova
CPC分类号： A61K47/32 , A61K9/0004
摘要： The present invention is related to materials and methods for forming polymeric delivery vehicles that reduces risk of oxidative degradation of a carried drug and the resulting compositions.
摘要翻译： 本发明涉及用于形成聚合物递送载体的材料和方法，其降低被携带药物和所得组合物的氧化降解的风险。
-
7.发明申请公开(公告)号：US20050101943A1
公开(公告)日：2005-05-12
申请号：US10978597
申请日：2004-11-01
申请人： Rupal Ayer , Scott Lautenbach , Michael Desjardin , Adrienne Higa
发明人： Rupal Ayer , Scott Lautenbach , Michael Desjardin , Adrienne Higa
CPC分类号： A61K9/0004
摘要： An osmotic pump system includes a capsule having at least one delivery port, a membrane plug retained at an open end of the capsule remote from the delivery port, the membrane plug providing a fluid-permeable barrier between an interior and an exterior of the capsule, and a removable imbibition rate reducer attachable to the capsule. The imbibition rate reducer comprises one or more flow controllers selected from the group consisting of an orifice having a selected size smaller than a surface area of the membrane plug and a membrane having a selected thickness, surface area, radial compression, and permeability. The imbibition rate reducer allows customizable delivery of medicaments.
摘要翻译： 渗透泵系统包括具有至少一个输送端口的胶囊，保持在远离输送端口的胶囊的开口端处的膜塞，膜塞在胶囊的内部和外部之间提供流体可渗透屏障， 以及可附接到胶囊的可移除的吸入减速器。 吸入减速器包括一个或多个流量控制器，其选自具有选定尺寸小于膜塞的表面积的孔口和选择的厚度，表面积，径向压缩和渗透性的膜。 吸入减速器允许定制的药物递送。
-
8.发明申请Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device 审中-公开稳定的非水性单相凝胶及其制剂用于从可植入装置输送公开(公告)号：US20090087408A1
公开(公告)日：2009-04-02
申请号：US12315194
申请日：2008-11-26
CPC分类号： A61K9/0004 , A61K9/0024 , A61K47/26 , A61L24/001
摘要： The present invention provides a suspension vehicle and suspension formulations deliverable from an implantable delivery device. In particular, the suspension vehicle of the present invention allows the formulation of beneficial agent suspensions that are stable over time at ambient and physiological temperatures. In addition, the beneficial agent suspensions formed using the suspension vehicle of the present invention allow controlled delivery of beneficial agent from an implanted delivery device over sustained periods of time, even when such delivery occurs at low flow rates, through a small-diameter delivery channel. Also included in the present invention are implantable delivery devices.
摘要翻译： 本发明提供了可从可植入递送装置递送的悬浮液和悬浮液制剂。 特别地，本发明的悬浮载体允许制备在环境和生理温度下随时间稳定的有益试剂悬浮液。 此外，使用本发明的悬浮载体形成的有益剂悬浮液允许从持久的时间段内从植入的输送装置控制递送有益剂，即使当这种递送以低流速通过小直径输送通道 。 本发明还包括可植入递送装置。
-
公开(公告)号：US20060263433A1
公开(公告)日：2006-11-23
申请号：US11347109
申请日：2006-02-03
申请人： Rupal Ayer , Paula Dennis , Michael Desjardin , Stan Lam , Kui Liu , James Matsuura , Latha Narayanan , Catherine Rohloff , Pauline Zamora
发明人： Rupal Ayer , Paula Dennis , Michael Desjardin , Stan Lam , Kui Liu , James Matsuura , Latha Narayanan , Catherine Rohloff , Pauline Zamora
CPC分类号： A61K38/21 , A61F2250/0068 , A61K9/0004 , A61K9/0019 , A61K9/0024 , A61K9/10 , A61K9/1617 , A61K9/1623 , A61K9/1694 , A61K9/19
摘要： A suspension formulation of interferon includes a non-aqueous, single-phase vehicle including at least one polymer and at least one solvent, the vehicle exhibiting viscous fluid characteristics, and an interferon contained in a particle formulation dispersed in the vehicle. The particle formulation includes a stabilizing component comprising one or more stabilizers selected from the group consisting of carbohydrates, antioxidants, and amino acids. The suspension formulation is characterized in that less than 10% of the interferon degrades over 3 months under an accelerated storage condition.
摘要翻译： 干扰素的悬浮液制剂包括非水性单相载体，其包含至少一种聚合物和至少一种溶剂，所述载体表现出粘性流体特性，以及包含在分散在载体中的颗粒制剂中的干扰素。 颗粒制剂包括稳定组分，其包含一种或多种选自碳水化合物，抗氧化剂和氨基酸的稳定剂。 悬浮液制剂的特征在于，在加速储存条件下，少于10％的干扰素在3个月内降解。
-
10.发明申请公开(公告)号：US20050008661A1
公开(公告)日：2005-01-13
申请号：US10814826
申请日：2004-03-31
CPC分类号： A61K47/32 , A61K9/0004
摘要： The present invention includes materials and methods for providing vehicles useful for providing drug formulations that address the potential drawbacks of known nonaqueous formulations. In particular, the present invention includes nonaqueous vehicles that are formed using a combination of polymer and solvent that results in a vehicle that is miscible in water. The nonaqueous vehicles facilitate the formulation of drug formulations that are stable over time, even when stored at, or exposed to, elevated temperatures. Moreover, the miscible vehicles of the present invention allow the preparation of drug formulations that work to reduce the occurrence of partial or complete occlusions of the delivery conduits included in delivery devices used to administer the drug formulations.
摘要翻译： 本发明包括用于提供可用于提供药物制剂的载体的材料和方法，其解决已知非水性制剂的潜在缺点。 特别地，本发明包括使用聚合物和溶剂的组合形成的非水载体，其导致在水中可混溶的载体。 非水性载体促进药物制剂的配制，其随着时间的推移是稳定的，即使在高温下储存或暴露于其中时也是如此。 此外，本发明的可混溶的载体允许制备药物制剂，其用于减少包括在用于施用药物制剂的递送装置中的输送管道的部分或完全闭塞的发生。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.032 秒)
